All In Biotech

Drug Trial Radar · NCT06147063

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

A Phase I, Open-label, Randomized, Active-Controlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 and AZD6563 Vaccine (ARTEMIS-C)

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 243 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

243

Actual

Start

Nov 27, 2023

Primary completion

Apr 30, 2024

Study completion Mar 27, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.

Conditions

  • COVID-19
  • SARS-CoV-2 Infection

Interventions

  • AZD9838Biological

    Intramuscular (IM) injection.

  • Licensed SARS-CoV-2 mRNA vaccineBiological

    Intramuscular (IM) injection.

  • AZD6563Biological

    Intramuscular (IM) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with immediate unsolicited adverse events (AE)Time frame: Within 30 minutes post vaccination
  2. Number of participants with injection site and systemic solicited adverse reactions (ARs)Time frame: Through 7 days post vaccination
  3. Number of participants with any unsolicited adverse events (AEs)Time frame: Through 28 days post vaccination
  4. Number of participants with serious adverse events (SAEs), Medically-attended adverse events (MAAEs), and Adverse Events of Special Interest (AESIs)Time frame: Through 12 months post vaccination
  5. Model-adjusted geometric mean titer (GMT) for SARS-CoV-2 ancestral strain neutralizing antibodiesTime frame: Day 29
  6. Model-adjusted geometric mean titer (GMT) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodiesTime frame: Day 29
  7. Model-adjusted geometric mean titer (GMT) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodiesTime frame: Day 29
  8. Geometric mean fold rise (GMFR) for SARS-CoV-2 ancestral strain neutralizing antibodiesTime frame: Day 1 to Day 29
  9. Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron BA.4/5 neutralizing antibodiesTime frame: Day 1 to Day 29
  10. Geometric mean fold rise (GMFR) for SARS-CoV-2 Omicron XBB.1.5 neutralizing antibodiesTime frame: Day 1 to Day 29
  11. Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 ancestral strainTime frame: Day 1 to Day 29
  12. Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron BA.4/5Time frame: Day 1 to Day 29
  13. Proportion of participants with neutralizing antibody seroresponse against SARS-CoV-2 Omicron XBB.1.5Time frame: Day 1 to Day 29

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Long Beach, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Chicago, Illinois

  • Research Site

    Wichita, Kansas

  • Research Site

    North Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.